The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MDS 2024 | The current treatment approaches for patients with VEXAS syndrome
Maël Heiblig, MD, Hôpital Lyon Sud, Lyon, France, discusses the current treatment approaches for patients with VEXAS syndrome, which include controlling inflammation, controlling the clone, and supportive care. Dr Heiblig hopes that prospective trials will be initiated in this patient population shortly to assess the safety and efficacy of the treatments being used, as no standard of care currently exists. This interview took place at the European School of Hematology 9th Translational Research Conference on Myelodysplastic Syndromes (ESH MDS) in Budapest, Hungary.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
